Literature DB >> 17344024

Increased NKCC1 expression in refractory human epilepsy.

Arjune Sen1, Lillian Martinian, Margareta Nikolic, Matthew C Walker, Maria Thom, Sanjay M Sisodiya.   

Abstract

Cation-chloride co-transporters (CCTs), particularly NKCC1, may be important in epileptogenesis. We have performed a detailed histological examination of NKCC1 in large samples of patients with hippocampal sclerosis (HS) or focal cortical dysplasia (FCD), pathologies both commonly associated with pharmacoresistant epilepsy. We consistently found increased immunoreactivity for NKCC1 in HS and FCD, but not in adjacent histologically normal cortex. Our results suggest that NKCC1 might contribute to the pathogenesis or pathophysiology of HS and FCD, thereby potentially offering a new therapeutic target in the treatment of pharmacoresistant epilepsy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17344024     DOI: 10.1016/j.eplepsyres.2007.01.004

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  20 in total

1.  Late development of the GABAergic system in the human cerebral cortex and white matter.

Authors:  Gang Xu; Kevin G Broadbelt; Robin L Haynes; Rebecca D Folkerth; Natalia S Borenstein; Richard A Belliveau; Felicia L Trachtenberg; Joseph J Volpe; Hannah C Kinney
Journal:  J Neuropathol Exp Neurol       Date:  2011-10       Impact factor: 3.685

Review 2.  Mechanisms of epileptogenesis in tuberous sclerosis complex and related malformations of cortical development with abnormal glioneuronal proliferation.

Authors:  Michael Wong
Journal:  Epilepsia       Date:  2007-08-28       Impact factor: 5.864

3.  Altered inhibition in tuberous sclerosis and type IIb cortical dysplasia.

Authors:  Delia M Talos; Hongyu Sun; Bela Kosaras; Annelise Joseph; Rebecca D Folkerth; Annapurna Poduri; Joseph R Madsen; Peter M Black; Frances E Jensen
Journal:  Ann Neurol       Date:  2012-03-23       Impact factor: 10.422

4.  Activated PKC{delta} and PKC{epsilon} inhibit epithelial chloride secretion response to cAMP via inducing internalization of the Na+-K+-2Cl- cotransporter NKCC1.

Authors:  Jun Tang; Patrice Bouyer; Andreas Mykoniatis; Mary Buschmann; Karl S Matlin; Jeffrey B Matthews
Journal:  J Biol Chem       Date:  2010-08-23       Impact factor: 5.157

5.  Combined effects of epileptic seizure and phenobarbital induced overexpression of P-glycoprotein in brain of chemically kindled rats.

Authors:  Xinyue Jing; Xiang Liu; Tao Wen; Shanshan Xie; Dan Yao; Xiaodong Liu; Guangji Wang; Lin Xie
Journal:  Br J Pharmacol       Date:  2010-03-03       Impact factor: 8.739

6.  Loss of cation-chloride cotransporter expression in preterm infants with white matter lesions: implications for the pathogenesis of epilepsy.

Authors:  Shenandoah Robinson; Irina Mikolaenko; Ian Thompson; Mark L Cohen; Monisha Goyal
Journal:  J Neuropathol Exp Neurol       Date:  2010-06       Impact factor: 3.685

7.  A Preliminary Study Evaluating the Safety and Efficacy of Bumetanide, an NKCC1 Inhibitor, in Patients with Drug-Resistant Epilepsy.

Authors:  Zeinab Gharaylou; Abbas Tafakhori; Elmira Agah; Vajihe Aghamollaii; Abbas Kebriaeezadeh; Mahmoudreza Hadjighassem
Journal:  CNS Drugs       Date:  2019-03       Impact factor: 5.749

8.  Impaired maturation of cortical GABA(A) receptor expression in pediatric epilepsy.

Authors:  Laura A Jansen; Lindsey D Peugh; William H Roden; Jeffrey G Ojemann
Journal:  Epilepsia       Date:  2010-02-03       Impact factor: 5.864

9.  Development of epileptiform excitability in the deep entorhinal cortex after status epilepticus.

Authors:  Denis E Bragin; Jennifer L Sanderson; Steven Peterson; John A Connor; Wolfgang S Müller
Journal:  Eur J Neurosci       Date:  2009-08-10       Impact factor: 3.386

10.  Pattern of P450 expression at the human blood-brain barrier: roles of epileptic condition and laminar flow.

Authors:  Chaitali Ghosh; Jorge Gonzalez-Martinez; Mohammed Hossain; Luca Cucullo; Vincent Fazio; Damir Janigro; Nicola Marchi
Journal:  Epilepsia       Date:  2010-01-13       Impact factor: 5.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.